Compare PEN & DECK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PEN | DECK |
|---|---|---|
| Founded | 2004 | 1973 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Shoe Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 14.0B |
| IPO Year | 2015 | 1996 |
| Metric | PEN | DECK |
|---|---|---|
| Price | $325.75 | $100.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 16 | 23 |
| Target Price | ★ $360.14 | $122.45 |
| AVG Volume (30 Days) | 476.6K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1155.56 | N/A |
| EPS | 4.52 | ★ 6.04 |
| Revenue | $1,403,665,000.00 | ★ $4,985,612,000.00 |
| Revenue This Year | $14.34 | $11.16 |
| Revenue Next Year | $13.71 | $6.96 |
| P/E Ratio | $72.14 | ★ $16.91 |
| Revenue Growth | ★ 17.50 | 16.28 |
| 52 Week Low | $221.26 | $78.91 |
| 52 Week High | $362.41 | $131.58 |
| Indicator | PEN | DECK |
|---|---|---|
| Relative Strength Index (RSI) | 38.65 | 39.51 |
| Support Level | $302.19 | $97.94 |
| Resistance Level | $335.61 | $105.32 |
| Average True Range (ATR) | 2.94 | 3.04 |
| MACD | -0.33 | -0.88 |
| Stochastic Oscillator | 15.04 | 1.48 |
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2025, Ugg and Hoka accounted for 51% and 45% of total sales, respectively. The firm also markets a niche sandal brand called Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores. It generated 64% of its fiscal 2025 sales in the United States.